IntroductIon the cumulative lifetime risk of having breast cancer is 65% (44%−78%) in BRCA1 gene mutation carriers and 45% (31%−56%) in BRCA2 carriers. For ovarian cancer, the risks are 39% (18%−54%) and 11% (2.4%−19%) for BRCA1 and BRCA2 carriers, respectively (1). risk management strategies in women with BRCA1 or BRCA2 mutation include cancer screening, chemoprevention, or risk-reducing surgery (2). cancer screening by different modalities aims at early detection of breast cancer, when it still is curable by appropriate treatment. Present recommendations for surveillance include annual breast magnetic resonance imaging (MrI), mammography, and ultrasound in addition to clinical breast examination and breast self-examination. the combination of MrI, mammography, and ultrasound has a sensitivity of 95% versus 45% for mammography as the only modality (3).
THE FREQUENCY AND OUTCOME OF BREAST CANCER RISK-REDUCING SURGERY IN FINNISH